Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Apellis Pharmaceuticals
APLS
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$32.45
-0.06
-0.18%
Last update: 12:02 PM
15 minutes delayed
Get Report
Comment
Apellis Pharmaceuticals (APLS) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Apellis Pharmaceuticals (NASDAQ:APLS) Stock
Apellis Pharmaceuticals Stock (NASDAQ: APLS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, September 23, 2024
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday
Avi Kapoor
Baird Maintains Outperform on Apellis Pharmac...
Benzinga Newsdesk
Friday, September 20, 2024
Mizuho Maintains Neutral on Apellis Pharmaceu...
Benzinga Newsdesk
Needham Reiterates Buy on Apellis Pharmaceuti...
Benzinga Newsdesk
What's Going With Apellis Pharmaceuticals Stock Friday?
Dylan Berman
Apellis Pharmaceuticals shares are trading lo...
Benzinga Newsdesk
The Committee For Medicinal Products For Huma...
Benzinga Newsdesk
Friday, September 13, 2024
Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals
Benzinga Insights
JP Morgan Maintains Overweight on Apellis Pha...
Benzinga Newsdesk
Tuesday, August 13, 2024
JP Morgan Maintains Overweight on Apellis Pha...
Benzinga Newsdesk
Friday, August 09, 2024
UBS Maintains Buy on Apellis Pharmaceuticals,...
Benzinga Newsdesk
Wedbush Maintains Neutral on Apellis Pharmace...
Benzinga Newsdesk
Goldman Sachs Maintains Buy on Apellis Pharma...
Benzinga Newsdesk
Baird Maintains Outperform on Apellis Pharmac...
Benzinga Newsdesk
Needham Reiterates Buy on Apellis Pharmaceuti...
Benzinga Newsdesk
Thursday, August 08, 2024
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
Vandana Singh
Apellis Pharmaceuticals shares are trading hi...
Benzinga Newsdesk
Trading Halt: Halt status updated at 7:25:00 ...
Benzinga Newsdesk
Apellis And Sobi Announce Phase 3 VALIANT Stu...
Benzinga Newsdesk
Trading Halt: Halted at 6:55:00 a.m. ET - Tra...
Benzinga Newsdesk
Friday, August 02, 2024
HC Wainwright & Co. Maintains Buy on Apellis ...
Benzinga Newsdesk
Goldman Sachs Maintains Buy on Apellis Pharma...
Benzinga Newsdesk
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
Benzinga Insights
Needham Reiterates Buy on Apellis Pharmaceuti...
Benzinga Newsdesk
Thursday, August 01, 2024
Apellis Pharmaceuticals shares are trading lo...
Benzinga Newsdesk
CORRECTION: Apellis Pharmaceuticals Q2 2024 G...
Benzinga Newsdesk
Wednesday, July 31, 2024
Jefferies Maintains Buy on Apellis Pharmaceut...
Benzinga Newsdesk
Watching Apellis Pharmaceuticals; Traders Cir...
Benzinga Newsdesk
Tuesday, July 30, 2024
Recursion to Report Q2 Earnings: What's in the Cards?
Zacks
Friday, July 26, 2024
Baird Maintains Outperform on Apellis Pharmac...
Benzinga Newsdesk
Tuesday, July 23, 2024
Baird Maintains Outperform on Apellis Pharmac...
Benzinga Newsdesk
Wednesday, July 17, 2024
Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights
Benzinga Insights
Goldman Sachs Maintains Buy on Apellis Pharma...
Benzinga Newsdesk
Friday, June 28, 2024
What Analysts Are Saying About Apellis Pharmaceuticals Stock
Benzinga Insights
Baird Maintains Outperform on Apellis Pharmac...
Benzinga Newsdesk
Apellis shares are trading lower after the co...
Benzinga Newsdesk
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Avi Kapoor
Apellis Committee Says It Plans To Seek Re-ex...
Benzinga Newsdesk
Friday, May 31, 2024
Piper Sandler Initiates Coverage On Apellis P...
Benzinga Newsdesk
Tuesday, May 28, 2024
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Apellis...
Benzinga Newsdesk
Friday, May 24, 2024
Apellis Pharmaceuticals And Sobi Announce Pos...
Benzinga Newsdesk
Thursday, May 23, 2024
Wells Fargo Maintains Equal-Weight on Apellis...
Benzinga Newsdesk
Tuesday, May 14, 2024
Apellis Pharmaceuticals Refinances Existing D...
Benzinga Newsdesk
Wednesday, May 08, 2024
Citigroup Maintains Buy on Apellis Pharmaceut...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Apellis...
Benzinga Newsdesk
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
Benzinga Insights
UBS Maintains Buy on Apellis Pharmaceuticals,...
Benzinga Newsdesk
Needham Reiterates Buy on Apellis Pharmaceuti...
Benzinga Newsdesk
Tuesday, May 07, 2024
Apellis Pharmaceuticals shares are trading lo...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch